These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 21436619)

  • 1. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Plk1 in cutaneous T-cell lymphomas (CTCLs).
    Liu XS; Liu X
    Cell Cycle; 2011 May; 10(10):1523. PubMed ID: 21478668
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
    Lansing TJ; McConnell RT; Duckett DR; Spehar GM; Knick VB; Hassler DF; Noro N; Furuta M; Emmitte KA; Gilmer TM; Mook RA; Cheung M
    Mol Cancer Ther; 2007 Feb; 6(2):450-9. PubMed ID: 17267659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
    Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
    Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
    Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
    Ergul M; Bakar-Ates F
    Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting expression or function of Plk1 in CTCL, that is a question.
    Wu S
    Cell Cycle; 2011 May; 10(10):1526. PubMed ID: 21478673
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
    Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL
    Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
    Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
    Chen Z; Chai Y; Zhao T; Li P; Zhao L; He F; Lang Y; Qin J; Ju H
    J Cell Physiol; 2019 May; 234(5):5904-5914. PubMed ID: 30488440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
    Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
    Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
    Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
    Russo MA; Kang KS; Di Cristofano A
    Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
    Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
    FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.